Literature DB >> 29981289

LncRNA HOXA-AS2 and its molecular mechanisms in human cancer.

Jicai Wang1, Zhilei Su1, Shounan Lu1, Wen Fu1, Zhifa Liu1, Xingming Jiang2, Sheng Tai3.   

Abstract

Long non-coding RNAs (lncRNAs), a novel class of noncoding RNAs, are commonly defined as RNA molecules more than 200 nucleotides in length. Emerging research indicated that lncRNA played a vital role in human tumorigenesis and progression by serving as tumor oncogenes or suppressors. LncRNA has been shown to get involved in participate various biological processes, such as cell growth, anti-apoptosis, migration and invasion. LncRNA HOXA cluster antisense RNA2 (HOXA-AS2) is a novel cancer-related lncRNA. It was recently found to exhibit aberrant expression in a variety of malignancies, including breast cancer, gastric cancer, gallbladder carcinoma, hepatocellular carcinoma and pancreatic cancer. The oncogenicity of lncRNA HOXA-AS2 mainly inhibits or promotes the expression of related genes through direct or indirect pathways, suggesting that HOXA-AS2 likely represents a feasible biomarker or therapeutic target in human cancers. In this review, we summarize current evidences concerning the biological functions and mechanisms of HOXA-AS2 during tumor development.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Diagnosis; HOXA-AS2; Prognosis; Therapeutic target; lncRNA

Mesh:

Substances:

Year:  2018        PMID: 29981289     DOI: 10.1016/j.cca.2018.07.004

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  93 in total

1.  LINC00200 contributes to the chemoresistance to oxaliplatin of gastric cancer cells via regulating E2F1/RAD51 axis.

Authors:  Mengxin Lin; Meifang Xu; Zongbin Xu; Zongqi Weng; Bingqiang Lin; Yanqin Lan; Qing Liu; Xiaoyan Lin; Jie Pan
Journal:  Hum Cell       Date:  2021-04-06       Impact factor: 4.174

2.  EnANNDeep: An Ensemble-based lncRNA-protein Interaction Prediction Framework with Adaptive k-Nearest Neighbor Classifier and Deep Models.

Authors:  Lihong Peng; Jingwei Tan; Xiongfei Tian; Liqian Zhou
Journal:  Interdiscip Sci       Date:  2022-01-10       Impact factor: 2.233

Review 3.  Tumor immune microenvironment lncRNAs.

Authors:  Eun-Gyeong Park; Sung-Jin Pyo; Youxi Cui; Sang-Ho Yoon; Jin-Wu Nam
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

Review 4.  There and Back Again: Hox Clusters Use Both DNA Strands.

Authors:  Elena L Novikova; Milana A Kulakova
Journal:  J Dev Biol       Date:  2021-07-15

5.  Long non-coding RNA MIAT regulates ox-LDL-induced cell proliferation, migration and invasion by miR-641/STIM1 axis in human vascular smooth muscle cells.

Authors:  Gang Ma; Shuting Bi; Pengfei Zhang
Journal:  BMC Cardiovasc Disord       Date:  2021-05-20       Impact factor: 2.298

6.  LncRNA LINC01857 promotes cell growth and diminishes apoptosis via PI3K/mTOR pathway and EMT process by regulating miR-141-3p/MAP4K4 axis in diffuse large B-cell lymphoma.

Authors:  Qian Li; Bao Li; Chang-Liang Lu; Jing-Ye Wang; Min Gao; Wei Gao
Journal:  Cancer Gene Ther       Date:  2020-12-12       Impact factor: 5.987

7.  LINC01433 targets miR-506-3p to promote the biological progress of nasopharyngeal carcinoma cells.

Authors:  Mingguang Zhou; Zhihuai Dong; Sunhong Hu; Mang Xiao
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-21       Impact factor: 2.503

8.  HOXA11-AS induces cisplatin resistance by modulating the microRNA-98/PBX3 axis in nasopharyngeal carcinoma.

Authors:  Haineng Li; Jia Huang; Sa Yu; Hangbo Li; Yan Zhou; Qingwei Wu
Journal:  Oncol Lett       Date:  2021-04-26       Impact factor: 2.967

9.  An Immune-Related lncRNA Expression Profile to Improve Prognosis Prediction for Lung Adenocarcinoma: From Bioinformatics to Clinical Word.

Authors:  Boxiang Zhang; Rui Wang; Kai Li; Ziyang Peng; Dapeng Liu; Yunfeng Zhang; Liuzhi Zhou
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

10.  Upregulation of lnc-ZNF281 Inhibits the Progression of Glioma via the AKT/GSK-3β/β-Catenin Signaling Pathway.

Authors:  Yu-Qin Deng; Gang-Yong Kong; Song Li; Fen Li; Si-Lu Wen
Journal:  J Immunol Res       Date:  2021-05-11       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.